ReviewCancers2025

CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2- Breast Cancer: Updated Meta-Analysis of Phase III Trials.

Stamatia Alexiou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.